![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: LSR |
Gene summary for LSR |
![]() |
Gene information | Species | Human | Gene symbol | LSR | Gene ID | 51599 |
Gene name | lipolysis stimulated lipoprotein receptor | |
Gene Alias | ILDR3 | |
Cytomap | 19q13.12 | |
Gene Type | protein-coding | GO ID | GO:0001889 | UniProtAcc | Q86X29 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
51599 | LSR | C08 | Human | Oral cavity | OSCC | 9.09e-88 | 1.90e+00 | 0.1919 |
51599 | LSR | C09 | Human | Oral cavity | OSCC | 7.77e-31 | 1.05e+00 | 0.1431 |
51599 | LSR | LN22 | Human | Oral cavity | OSCC | 5.47e-20 | 2.04e+00 | 0.1733 |
51599 | LSR | LN38 | Human | Oral cavity | OSCC | 8.31e-12 | 2.79e+00 | 0.168 |
51599 | LSR | LN46 | Human | Oral cavity | OSCC | 2.95e-44 | 1.93e+00 | 0.1666 |
51599 | LSR | LP15 | Human | Oral cavity | LP | 9.17e-06 | 2.14e+00 | 0.2174 |
51599 | LSR | LP17 | Human | Oral cavity | LP | 3.67e-06 | 1.19e+00 | 0.2349 |
51599 | LSR | SYSMH1 | Human | Oral cavity | OSCC | 2.11e-34 | 8.18e-01 | 0.1127 |
51599 | LSR | SYSMH2 | Human | Oral cavity | OSCC | 2.61e-23 | 9.69e-01 | 0.2326 |
51599 | LSR | SYSMH3 | Human | Oral cavity | OSCC | 3.30e-39 | 1.16e+00 | 0.2442 |
51599 | LSR | SYSMH6 | Human | Oral cavity | OSCC | 3.77e-15 | 4.72e-01 | 0.1275 |
51599 | LSR | GSM5252130_BPH340PrGF_Via | Human | Prostate | BPH | 1.52e-15 | 8.08e-01 | -0.1972 |
51599 | LSR | GSM5252131_BPH340PrSF_Via | Human | Prostate | BPH | 2.75e-09 | 5.68e-01 | -0.2126 |
51599 | LSR | GSM5252135_BPH511PrPUr_Fcol_3GEX | Human | Prostate | BPH | 1.11e-08 | 7.17e-01 | -0.1833 |
51599 | LSR | 047563_1562-all-cells | Human | Prostate | BPH | 3.05e-15 | -2.46e-01 | 0.0791 |
51599 | LSR | Dong_P1 | Human | Prostate | Tumor | 4.92e-27 | 1.51e-01 | 0.035 |
51599 | LSR | Dong_P3 | Human | Prostate | Tumor | 2.23e-13 | -1.40e-02 | 0.0278 |
51599 | LSR | Dong_P4 | Human | Prostate | Tumor | 1.78e-11 | 3.37e-01 | 0.0292 |
51599 | LSR | Dong_P5 | Human | Prostate | Tumor | 1.90e-25 | 2.62e-01 | 0.053 |
51599 | LSR | GSM5353243_PA_PR5261_T1_S23_L002 | Human | Prostate | Tumor | 6.36e-07 | -1.85e-01 | 0.1545 |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00487329 | Breast | Precancer | gland development | 49/1080 | 436/18723 | 6.11e-06 | 1.73e-04 | 49 |
GO:00018898 | Breast | Precancer | liver development | 21/1080 | 147/18723 | 1.08e-04 | 1.96e-03 | 21 |
GO:00610088 | Breast | Precancer | hepaticobiliary system development | 21/1080 | 150/18723 | 1.45e-04 | 2.49e-03 | 21 |
GO:00508789 | Breast | Precancer | regulation of body fluid levels | 40/1080 | 379/18723 | 1.68e-04 | 2.77e-03 | 40 |
GO:00356335 | Breast | Precancer | maintenance of blood-brain barrier | 8/1080 | 35/18723 | 6.95e-04 | 8.43e-03 | 8 |
GO:00018948 | Breast | Precancer | tissue homeostasis | 27/1080 | 268/18723 | 3.49e-03 | 2.90e-02 | 27 |
GO:004873214 | Breast | IDC | gland development | 64/1434 | 436/18723 | 3.47e-07 | 1.74e-05 | 64 |
GO:003297014 | Breast | IDC | regulation of actin filament-based process | 56/1434 | 397/18723 | 6.37e-06 | 1.99e-04 | 56 |
GO:003295614 | Breast | IDC | regulation of actin cytoskeleton organization | 48/1434 | 358/18723 | 1.03e-04 | 1.96e-03 | 48 |
GO:005087813 | Breast | IDC | regulation of body fluid levels | 50/1434 | 379/18723 | 1.12e-04 | 2.10e-03 | 50 |
GO:006056212 | Breast | IDC | epithelial tube morphogenesis | 44/1434 | 325/18723 | 1.58e-04 | 2.73e-03 | 44 |
GO:00303244 | Breast | IDC | lung development | 28/1434 | 177/18723 | 1.90e-04 | 3.15e-03 | 28 |
GO:00303234 | Breast | IDC | respiratory tube development | 28/1434 | 181/18723 | 2.78e-04 | 4.26e-03 | 28 |
GO:00611383 | Breast | IDC | morphogenesis of a branching epithelium | 28/1434 | 182/18723 | 3.05e-04 | 4.60e-03 | 28 |
GO:000188913 | Breast | IDC | liver development | 24/1434 | 147/18723 | 3.29e-04 | 4.92e-03 | 24 |
GO:00605412 | Breast | IDC | respiratory system development | 30/1434 | 203/18723 | 3.85e-04 | 5.40e-03 | 30 |
GO:006100813 | Breast | IDC | hepaticobiliary system development | 24/1434 | 150/18723 | 4.46e-04 | 6.04e-03 | 24 |
GO:00017635 | Breast | IDC | morphogenesis of a branching structure | 29/1434 | 196/18723 | 4.68e-04 | 6.26e-03 | 29 |
GO:003514812 | Breast | IDC | tube formation | 23/1434 | 148/18723 | 8.79e-04 | 1.02e-02 | 23 |
GO:000183812 | Breast | IDC | embryonic epithelial tube formation | 19/1434 | 121/18723 | 2.10e-03 | 1.97e-02 | 19 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
LSR | SNV | Missense_Mutation | rs748784670 | c.686N>G | p.Asn229Ser | p.N229S | Q86X29 | protein_coding | deleterious(0.01) | possibly_damaging(0.833) | TCGA-A1-A0SK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
LSR | SNV | Missense_Mutation | c.1340N>T | p.Ser447Phe | p.S447F | Q86X29 | protein_coding | tolerated(0.73) | benign(0.006) | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
LSR | SNV | Missense_Mutation | c.1636N>G | p.Ser546Ala | p.S546A | Q86X29 | protein_coding | tolerated(0.15) | benign(0.005) | TCGA-AN-A0FL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
LSR | SNV | Missense_Mutation | c.1393N>G | p.Pro465Ala | p.P465A | Q86X29 | protein_coding | tolerated(0.28) | benign(0.027) | TCGA-AR-A256-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD | |
LSR | SNV | Missense_Mutation | c.1631N>G | p.Pro544Arg | p.P544R | Q86X29 | protein_coding | tolerated(0.07) | benign(0.221) | TCGA-D8-A147-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine | SD | |
LSR | SNV | Missense_Mutation | c.424N>T | p.Pro142Ser | p.P142S | Q86X29 | protein_coding | tolerated(0.09) | benign(0.082) | TCGA-E2-A1LB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
LSR | SNV | Missense_Mutation | rs775741599 | c.712G>A | p.Val238Ile | p.V238I | Q86X29 | protein_coding | deleterious(0) | probably_damaging(0.937) | TCGA-E2-A574-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
LSR | deletion | Frame_Shift_Del | novel | c.629delN | p.Asp212ThrfsTer46 | p.D212Tfs*46 | Q86X29 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
LSR | SNV | Missense_Mutation | rs755436260 | c.1000G>A | p.Ala334Thr | p.A334T | Q86X29 | protein_coding | tolerated(0.28) | benign(0.011) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
LSR | SNV | Missense_Mutation | rs372794690 | c.1246N>A | p.Asp416Asn | p.D416N | Q86X29 | protein_coding | deleterious(0.03) | probably_damaging(0.997) | TCGA-AZ-6601-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |